Bioinformatics & Multi-Omics
A biomarker that has not been validated is a finding, not an asset
USD 120–380K · 16–28 weeks · Validated panel with statistical performance package and assay protocol
At a glance
- Price band
- USD 120–380K
- Duration
- 16–28 weeks
- Deliverable
- Validated panel + assay
- Evidence
- Independent cohort
Indicative list price. Final scope and price confirmed in the proposal.
Talk to a scientistThe problem
Why teams buy this
Published biomarkers rarely reproduce. Sponsors need candidates that survive independent validation in the real sample matrix, with an assay already built - because that is the difference between an interesting result and something you can put into a trial or a product.
What you get
Deliverables, not activity
- A validated biomarker panel
- A statistical performance package: sensitivity, specificity, ROC, confidence intervals
- A validated assay protocol in the intended sample type
- Regulatory-ready validation documentation
How it works
The sequence
Cohort and endpoint definitionComputational discovery and statistical modellingPrioritisation against assay feasibilityAssay build and analytical validationIndependent cohort confirmation
Note the third step. We prioritise candidates partly on whether they can be measured reliably, which is why our panels tend to survive the transition to assay.
Who this is for
Pharma translational medicine · diagnostics companies · academic medical centres · precision-medicine programmes.
Proof
Representative result
A six-protein panel discovered from 480 samples, validated by qPCR and immunoassay, achieving AUC 0.89 in an independent cohort.
Representative programme - illustrates typical scope and outcomes; not an individual client account. Client-specific references are available on request under confidentiality.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.